Pyxis Oncology — Third Quarter 2026 Earnings Summary

Pyxis Oncology reported third-quarter 2026 financial results showing a net loss of $20.0 million and cash resources sufficient to fund operations into the first half of 2028. The company announced updated Phase 1 monotherapy data for its lead candidate, micvotabart pelidotin (MICVO), in patients with recurrent/metastatic head and neck squamous cell carcinoma, demonstrating a 36% confirmed objective response rate and a manageable safety profile. Pyxis Oncology has aligned with FDA and EMA feedback on the design of the global Phase 3 Headliner trial, which is planned to initiate in mid-2027. Additionally, the company completed a public offering in October 2026 generating approximately $110.0 million in upfront proceeds and appointed Tom Civik as Chief Executive Officer and Chairman.